Search
Menu
Home
HTB
2017
November
24
HTB
24 November 2017
Contents
Antiretrovirals
Coformulated dolutegravir plus rilpivirine approved in US (Juluca)
Darunavir-based single pill FDC approved in EU (Symtuza)